SAFE Score Identified Best for Cirrhosis Risk Prediction
A study of over 850,000 veterans found the SAFE score accurately predicted long-term cirrhosis and cancer risks.
Updated on Sept. 24, 2026 in Nutrition
Live Poll
Do you trust that new screening tools for chronic diseases lead to better patient care?
Researchers have determined that the SAFE score provided the highest net benefit for predicting a 10-year risk of cirrhosis among nine different diagnostic tools evaluated. The assessment tool utilizes clinical data including patient age, BMI, and metabolic markers to identify liver health risks in primary care settings.
Why it matters
Existing risk scores often lack the necessary sensitivity and specificity to identify liver conditions that are frequently clinically silent. Improving detection accuracy helps clinicians avoid unnecessary secondary testing while identifying patients at risk of cirrhosis and liver cancer.
The study utilized a cohort of 853,131 veterans with a median age of 61 and a median BMI of 31.3. A SAFE score of 29.5 corresponds to a 2.5% cirrhosis risk, while a score of 43.8 aligns with a 0.25% risk for hepatocellular carcinoma over 10 years.
The players
Yale School of Medicine
This institution served as the academic affiliation for the study researchers who conducted the analysis of liver disease risk scores.
U.S. Veterans Affairs
This national health system provided the comprehensive dataset of 853,131 patients that enabled the comparative study.
The details
The SAFE calculator identifies risk based on factors including diabetes status, platelets, globulins, and liver enzymes such as aspartate and alanine aminotransferase. Researchers analyzed data from the national U.S. Veterans Affairs health system collected from 2008 to 2020 to validate these findings among patients with noncirrhotic steatotic liver disease.
Timeline
The data collection period for the study population spanned from 2008 to 2020.
The clinical risk prediction tool evaluated outcomes over a timeframe of 10 years.
The Big Picture
This finding challenges the current reliance on standard primary care cirrhosis screening protocols that often fail to catch asymptomatic disease. By establishing the superior predictive power of the SAFE score, the research suggests a potential transition toward more precise, data-driven diagnostic methods.
Patients with steatotic liver disease may see doctors adopt this multi-factor calculator to more accurately determine their long-term health risks. This approach could reduce the frequency of invasive secondary testing for individuals who fall into lower-risk categories based on their metabolic markers.
The takeaway
The study demonstrates that integrating blood and metabolic markers into a single score can significantly improve the accuracy of early liver disease detection. Clinicians can use these findings to better stratify patients and prioritize those who require more intensive medical monitoring.
Further reading
For more information on digestive and liver health, see the Nutrition section.
Source note: This article includes information reported by MedPage Today.
Live Poll
Do you trust that new screening tools for chronic diseases lead to better patient care?
